Disease pathology and progression arise not only from genetic alterations but also from the changes in phenotype brought on by epigenetic modifications in transcription and expression.

Our team has broad experience working on all classes of epigenetic targets, including bromodomains, methyltransferases and demethylases, ubiquitin ligases and deubiquitinases, and histone deacetylases, encompassing target discovery, assay development and screening, in silico library design and medicinal chemistry. We are proud to have contributed to the discovery of belinsotat, an approved drug for refractory peripheral T-cell lymphoma that works by inhibiting an epigenetic target.